Literature DB >> 28903966

Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre, randomised controlled trial: design and methodology.

Gus Gazzard1,2, Evgenia Konstantakopoulou1,2,3, David Garway-Heath1,2, Keith Barton1, Richard Wormald1,2, Stephen Morris4, Rachael Hunter5, Gary Rubin2, Marta Buszewicz6, Gareth Ambler7, Catey Bunce1,8,9.   

Abstract

PURPOSE: The Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial aims to establish whether initial treatment with selective laser trabeculoplasty (SLT) is superior to initial treatment with topical medication for primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
DESIGN: The LiGHT Trial is a prospective, unmasked, multicentre, pragmatic, randomised controlled trial. 718 previously untreated patients with POAG or OHT were recruited at six collaborating centres in the UK between 2012 and 2014. The trial comprises two treatment arms: initial SLT followed by conventional medical therapy as required, and medical therapy without laser therapy. Randomisation was provided online by a web-based randomisation service. Participants will be monitored for 3 years, according to routine clinical practice. The target intraocular pressure (IOP) was set at baseline according to an algorithm, based on disease severity and lifetime risk of loss of vision at recruitment, and subsequently adjusted on the basis of IOP control, optic disc and visual field. The primary outcome measure is health-related quality of life (HRQL) (EQ-5D five-level). Secondary outcomes are treatment pathway cost and cost-effectiveness, Glaucoma Utility Index, Glaucoma Symptom Scale, Glaucoma Quality of Life, objective measures of pathway effectiveness, visual function and safety profiles and concordance. A single main analysis will be performed at the end of the trial on an intention-to-treat basis.
CONCLUSIONS: The LiGHT Trial is a multicentre, pragmatic, randomised clinical trial that will provide valuable data on the relative HRQL, clinical effectiveness and cost-effectiveness of SLT and topical IOP-lowering medication. TRIAL REGISTRATION NUMBER: ISRCTN32038223, Pre-results. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  glaucoma; intraocular pressure; treatment lasers

Mesh:

Substances:

Year:  2017        PMID: 28903966     DOI: 10.1136/bjophthalmol-2017-310877

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  9 in total

Review 1.  Laser trabeculoplasty for open-angle glaucoma and ocular hypertension.

Authors:  Christiane R Rolim-de-Moura; Augusto Paranhos; Mohamed Loutfi; David Burton; Richard Wormald; Jennifer R Evans
Journal:  Cochrane Database Syst Rev       Date:  2022-08-09

Review 2.  A Review of Selective Laser Trabeculoplasty: "The Hype Is Real".

Authors:  Tomislav Sarenac; Anela Bečić Turkanović; Peter Ferme; Tomaž Gračner
Journal:  J Clin Med       Date:  2022-07-04       Impact factor: 4.964

3.  Peripheral anterior synechiae after selective laser trabeculoplasty among Chinese patients.

Authors:  Jonathan Cheuk-Hung Chan; Rachel Ka-Ying Cheung; Perseus Wing-Fu Wong; Jimmy Shiu-Ming Lai
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-05-07       Impact factor: 3.535

Review 4.  Review of glaucoma medication adherence monitoring in the digital health era.

Authors:  Alaa Erras; Bita Shahrvini; Robert N Weinreb; Sally L Baxter
Journal:  Br J Ophthalmol       Date:  2021-04-15       Impact factor: 5.908

5.  Outcome of Selective Laser Trabeculoplasty in Young Patients with Primary Open-Angle Glaucoma and Ocular Hypertension.

Authors:  Dan Liu; Di Chen; Qian Tan; Xiaobo Xia; Haibo Jiang; Jian Jiang
Journal:  J Ophthalmol       Date:  2020-06-09       Impact factor: 1.909

6.  Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial.

Authors:  Gus Gazzard; Evgenia Konstantakopoulou; David Garway-Heath; Anurag Garg; Victoria Vickerstaff; Rachael Hunter; Gareth Ambler; Catey Bunce; Richard Wormald; Neil Nathwani; Keith Barton; Gary Rubin; Marta Buszewicz
Journal:  Lancet       Date:  2019-03-09       Impact factor: 79.321

7.  Designs and Methodologies Used in Landmark Clinical Trials of Glaucoma: Implications for Future Big Data Mining and Actionable Disease Treatment.

Authors:  Saif Aldeen AlRyalat; Monica K Ertel; Leonard K Seibold; Malik Y Kahook
Journal:  Front Med (Lausanne)       Date:  2022-01-26

8.  Is selective laser trabeculoplasty shifting the glaucoma treatment paradigm in developing countries?

Authors:  Evgenia Konstantakopoulou; Gus Gazzard
Journal:  Br J Ophthalmol       Date:  2022-05-13       Impact factor: 5.908

9.  Eye health and quality of life: an umbrella review protocol.

Authors:  Lama Assi; Lori Rosman; Fatimah Chamseddine; Perla Ibrahim; Hadi Sabbagh; Nathan Congdon; Jennifer Evans; Jacqueline Ramke; Hannah Kuper; Matthew J Burton; Joshua R Ehrlich; Bonnielin K Swenor
Journal:  BMJ Open       Date:  2020-08-30       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.